Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS) Oct 20, 2023 02:00AM
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies Jul 7, 2022 12:00AM